Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies

Clifton Bingham, A. I. Sebba, B. R. Rubin, G. E. Ruoff, J. Kremer, S. Bird, S. S. Smugar, B. J. Fitzgerald, K. O'Brien, A. M. Tershakovec

Research output: Contribution to journalArticle

Abstract

Objective. To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies. Methods. Two multi-centre, 26-week, double-blind, placebo-controlled, non-inferiority studies were conducted, enrolling patients who were prior non-steroidal anti-inflammatory drug (NSAID) or acetaminophen users. There were 599 patients in study 1 and 608 patients in study 2 randomized 4:4:1:1 to etoricoxib 30 mg qd, celecoxib 200 mg qd or one of two placebo groups for 12 weeks. After 12 weeks, placebo patients were evenly distributed to etoricoxib or celecoxib based on their initial enrollment randomization schedule. The primary hypothesis was that etoricoxib 30 mg would be at least as effective as celecoxib 200 mg for the time-weighted average change from baseline over 12 weeks for Western Ontario and McMaster (WOMAC) Pain Subscale, WOMAC Physical Function Subscale and Patient Global Assessment of Disease Status. Active treatments were also assessed over the full 26 weeks. Adverse experiences were collected for safety assessment. Results. In both studies, etoricoxib was non-inferior to celecoxib for all three efficacy outcomes over 12 and 26 weeks; both were superior to placebo (P <0.001) for all three outcomes in each study over 12 weeks. The safety and tolerability of etoricoxib 30 mg qd and celecoxib 200 mg qd were similar over 12 and 26 weeks. Conclusions. Etoricoxib 30mg qd was at least as effective as celecoxib 200 mg qd and had similar safety in the treatment of knee and hip OA; both were superior to placebo.

Original languageEnglish (US)
Pages (from-to)496-507
Number of pages12
JournalRheumatology
Volume46
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

etoricoxib
Celecoxib
Osteoarthritis
Placebos
Safety
Therapeutics
Hip Osteoarthritis
Knee Osteoarthritis
Ontario
Acetaminophen
Random Allocation

Keywords

  • Celecoxib
  • COX-2 inhibitor
  • Efficacy
  • Etoricoxib
  • Osteoarthritis
  • WOMAC

ASJC Scopus subject areas

  • Neuroscience(all)
  • Rheumatology

Cite this

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. / Bingham, Clifton; Sebba, A. I.; Rubin, B. R.; Ruoff, G. E.; Kremer, J.; Bird, S.; Smugar, S. S.; Fitzgerald, B. J.; O'Brien, K.; Tershakovec, A. M.

In: Rheumatology, Vol. 46, No. 3, 03.2007, p. 496-507.

Research output: Contribution to journalArticle

Bingham, Clifton ; Sebba, A. I. ; Rubin, B. R. ; Ruoff, G. E. ; Kremer, J. ; Bird, S. ; Smugar, S. S. ; Fitzgerald, B. J. ; O'Brien, K. ; Tershakovec, A. M. / Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. In: Rheumatology. 2007 ; Vol. 46, No. 3. pp. 496-507.
@article{3713115c7b2447af9bccb00c8a3fae2d,
title = "Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies",
abstract = "Objective. To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies. Methods. Two multi-centre, 26-week, double-blind, placebo-controlled, non-inferiority studies were conducted, enrolling patients who were prior non-steroidal anti-inflammatory drug (NSAID) or acetaminophen users. There were 599 patients in study 1 and 608 patients in study 2 randomized 4:4:1:1 to etoricoxib 30 mg qd, celecoxib 200 mg qd or one of two placebo groups for 12 weeks. After 12 weeks, placebo patients were evenly distributed to etoricoxib or celecoxib based on their initial enrollment randomization schedule. The primary hypothesis was that etoricoxib 30 mg would be at least as effective as celecoxib 200 mg for the time-weighted average change from baseline over 12 weeks for Western Ontario and McMaster (WOMAC) Pain Subscale, WOMAC Physical Function Subscale and Patient Global Assessment of Disease Status. Active treatments were also assessed over the full 26 weeks. Adverse experiences were collected for safety assessment. Results. In both studies, etoricoxib was non-inferior to celecoxib for all three efficacy outcomes over 12 and 26 weeks; both were superior to placebo (P <0.001) for all three outcomes in each study over 12 weeks. The safety and tolerability of etoricoxib 30 mg qd and celecoxib 200 mg qd were similar over 12 and 26 weeks. Conclusions. Etoricoxib 30mg qd was at least as effective as celecoxib 200 mg qd and had similar safety in the treatment of knee and hip OA; both were superior to placebo.",
keywords = "Celecoxib, COX-2 inhibitor, Efficacy, Etoricoxib, Osteoarthritis, WOMAC",
author = "Clifton Bingham and Sebba, {A. I.} and Rubin, {B. R.} and Ruoff, {G. E.} and J. Kremer and S. Bird and Smugar, {S. S.} and Fitzgerald, {B. J.} and K. O'Brien and Tershakovec, {A. M.}",
year = "2007",
month = "3",
doi = "10.1093/rheumatology/kel296",
language = "English (US)",
volume = "46",
pages = "496--507",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies

AU - Bingham, Clifton

AU - Sebba, A. I.

AU - Rubin, B. R.

AU - Ruoff, G. E.

AU - Kremer, J.

AU - Bird, S.

AU - Smugar, S. S.

AU - Fitzgerald, B. J.

AU - O'Brien, K.

AU - Tershakovec, A. M.

PY - 2007/3

Y1 - 2007/3

N2 - Objective. To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies. Methods. Two multi-centre, 26-week, double-blind, placebo-controlled, non-inferiority studies were conducted, enrolling patients who were prior non-steroidal anti-inflammatory drug (NSAID) or acetaminophen users. There were 599 patients in study 1 and 608 patients in study 2 randomized 4:4:1:1 to etoricoxib 30 mg qd, celecoxib 200 mg qd or one of two placebo groups for 12 weeks. After 12 weeks, placebo patients were evenly distributed to etoricoxib or celecoxib based on their initial enrollment randomization schedule. The primary hypothesis was that etoricoxib 30 mg would be at least as effective as celecoxib 200 mg for the time-weighted average change from baseline over 12 weeks for Western Ontario and McMaster (WOMAC) Pain Subscale, WOMAC Physical Function Subscale and Patient Global Assessment of Disease Status. Active treatments were also assessed over the full 26 weeks. Adverse experiences were collected for safety assessment. Results. In both studies, etoricoxib was non-inferior to celecoxib for all three efficacy outcomes over 12 and 26 weeks; both were superior to placebo (P <0.001) for all three outcomes in each study over 12 weeks. The safety and tolerability of etoricoxib 30 mg qd and celecoxib 200 mg qd were similar over 12 and 26 weeks. Conclusions. Etoricoxib 30mg qd was at least as effective as celecoxib 200 mg qd and had similar safety in the treatment of knee and hip OA; both were superior to placebo.

AB - Objective. To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies. Methods. Two multi-centre, 26-week, double-blind, placebo-controlled, non-inferiority studies were conducted, enrolling patients who were prior non-steroidal anti-inflammatory drug (NSAID) or acetaminophen users. There were 599 patients in study 1 and 608 patients in study 2 randomized 4:4:1:1 to etoricoxib 30 mg qd, celecoxib 200 mg qd or one of two placebo groups for 12 weeks. After 12 weeks, placebo patients were evenly distributed to etoricoxib or celecoxib based on their initial enrollment randomization schedule. The primary hypothesis was that etoricoxib 30 mg would be at least as effective as celecoxib 200 mg for the time-weighted average change from baseline over 12 weeks for Western Ontario and McMaster (WOMAC) Pain Subscale, WOMAC Physical Function Subscale and Patient Global Assessment of Disease Status. Active treatments were also assessed over the full 26 weeks. Adverse experiences were collected for safety assessment. Results. In both studies, etoricoxib was non-inferior to celecoxib for all three efficacy outcomes over 12 and 26 weeks; both were superior to placebo (P <0.001) for all three outcomes in each study over 12 weeks. The safety and tolerability of etoricoxib 30 mg qd and celecoxib 200 mg qd were similar over 12 and 26 weeks. Conclusions. Etoricoxib 30mg qd was at least as effective as celecoxib 200 mg qd and had similar safety in the treatment of knee and hip OA; both were superior to placebo.

KW - Celecoxib

KW - COX-2 inhibitor

KW - Efficacy

KW - Etoricoxib

KW - Osteoarthritis

KW - WOMAC

UR - http://www.scopus.com/inward/record.url?scp=33847420941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847420941&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kel296

DO - 10.1093/rheumatology/kel296

M3 - Article

C2 - 16936327

AN - SCOPUS:33847420941

VL - 46

SP - 496

EP - 507

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 3

ER -